Abstract
Osteoporosis is a chronic disease with high unmet med- ical need. It is characterized by low bone mass and deteriorated bone architecture, leading to increased risk of fragility fractures, with vertebral and hip frac- tures representing the highest risk of morbidity and mor tality.
The baseline therapeutic approach to oste- oporosis treatment has been based on adequate intake of calcium and supplementation of vitamin D. In this review, we focus on two approved monoclonal anti- bodies, romosozumab and denosumab, which have been shown to be efficient and safe options to prevent patient fractures.
Romosozumab is a humanized mono- clonal antibody IgG2 isotype that extracellularly binds sclerostin with high affinity and specificity. Denos- umab is a fully human monoclonal antibody IgG2 iso- type that binds RANK ligand (RANKL) and prevents the interaction of RANKL with its receptor RANK.
Denos- umab is an antiresorptive that has been used for more than a decade, and romosozumab has recently been approved for clinical practice worldwide.